Eastman Chemical Company is facing a severe financial downturn, with a staggering 59.4% projected decline in earnings to $0.76 per share. In response, the company has announced $175 million in cost reductions to mitigate its losses, coinciding with a troubling 26.63% year-over-year drop in total shareholder returns. While analysts have mixed sentiments—with Citi raising its price target to $75 and RBC downgrading—ongoing demand weaknesses pose significant challenges, as reflected in a 12.1% revenue drop and ongoing underperformance in the market.
Loading timeline…